Neurophet, an AI company developing neuroimaging analysis software, has appointed neuroradiologist Lawrence Tanenbaum, MD, as scientific advisor.
Tanenbaum has more than 30 years of experience in clinical practice, academic research, and healthcare technology. He most recently served as vice president and chief technology officer at RadNet, where he led imaging technology strategy and AI integration across a national imaging network.
Prior to RadNet, he served as director of MRI, CT, and advanced imaging and associate professor of radiology at the Icahn School of Medicine at Mount Sinai in New York City. He is a fellow of the American College of Radiology (ACR), has served on the Roster of Distinguished Scientific Advisors of RSNA, and has held advisory roles at more than 20 AI and imaging companies.
Neurophet's AI-powered neuroimaging portfolio includes brain MRI analysis software, PET image quantitative analysis software, and tools for Alzheimer's disease treatment monitoring and multiple sclerosis image analysis. The company recently received clearance from the U.S. Food and Drug Administration (FDA) for an updated version of its brain MRI analysis software, Neurophet Aqua AD Plus.
